Walters Group

CIK: 0001177523

Transaction Breakdown

Open Market Buys (P)2 (100.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ZNTL

Zentalis Pharmaceuticals, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (2 total)

ZNTL
Zentalis Pharmaceuticals, Inc.
Aug 14, 2026
Purchase(P)
Direct
4.3M shares at avg. $3.50$15.2M
ZNTL
Zentalis Pharmaceuticals, Inc.
Dec 31, 2025
Purchase(P)
Direct
6.5M shares at avg. $1.20$7.8M

		Type	Shares	Price		Ownership
Aug 14, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Purchase(P)	4,335,000	$3.50	$15,172,500	Direct
Dec 31, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Purchase(P)	6,459,973	$1.20	$7,751,968	Direct

1-2 of 2 transactions

About WALTERS GROUP

WALTERS GROUP (SEC CIK 0001177523) files insider reports with the SEC as 10% Owner of Zentalis Pharmaceuticals, Inc. (ZNTL).

Signal8 holds 3 ownership filings by WALTERS GROUP (1 Form 3, 2 Form 4), filed between Jan 8, 2026 and Aug 19, 2026. Those filings report 2 transactions, from Dec 31, 2025 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on WALTERS GROUP's filings is in HENDERSON, NV.

Recent filings by WALTERS GROUP

Aug 14, 2026: Open-market purchase of ZNTL shares (Form 4, code P).
Dec 31, 2025: Open-market purchase of ZNTL shares (Form 4, code P).

Other insiders filing for Zentalis Pharmaceuticals, Inc. (ZNTL)

Bruns Ingmar, Chief Medical Officer
Johnson David Michael, Director
Skvarka Jan, Director
Walker Luke Nathaniel, Director
Kariuki Enoch, Director
Myers Scott Dunseth, Director

How to read Form 4 transaction codes